CTLA4 and melanoma: In addition, we applied the poorly immunogenic and highly aggressive B16F10 melanoma model, again demonstrating that GNE-KO delayed tumor growth, prolonged survival, and increased sensitivity to PD-1/CTLA-4 blockade, resulting in a more pronounced delay in tumor growth and a longer survival of mice bearing GNE-KO tumors (fig.